New paper on Pritumumab Released by Nascent Biologics Co-founder Glassy

Nascent Biologics co-founder Mark C. Glassy has co-authored a new paper entitled “Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab.”

Published in Human Antibodies 18, the paper covers the performance of pritumumab in patients with brain cancer.

The bottom line:

Pritumumab appears to be a safe and effective therapy in patients with malignant gliomas.

Click here to download a PDF copy of the complete paper